This content is restricted.
Brief
On July 18, 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) issued an update regarding "MHRA approves adrenaline nasal spray - the first needle-free emergency treatment for anaphylaxis in the UK". The MHRA approved adrenaline nasal spray (EURneffy), a ready-to-use single dose nasal spray, to treat serious allergic reactions. This approval provides a new option for emergency treatment of anaphylaxis, which is a sudden and potentially life-threatening condition.
Highlights content goes here...
This content is restricted.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested